Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $19 to $17.
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $19 to $17.